CD274 and non-small cell lung carcinoma: MS analyses of LQDAGVYR and AEVIWTSSDHQVLSGK at baseline and at 9 and 28 days of the acceleration protocol indicated that PD-L1 levels were not decreased in the NSCLC samples, in contrast to IHC measurements (Fig. 7).